Discover a study that has revealed a new potential mechanism of understanding inflammation in ulcerative colitis.

To evaluate the therapeutic value of mirikizumab in IBD, researchers conducted a systematic review and meta-analysis of ...

Johnson & Johnson (J&J) has shared positive long-term results from a phase 3 trial of its dual-acting IL-23 inhibitor Tremfya ...

The research also predicts inflammatory bowel disease diagnoses will likely double in Aotearoa in the next 20 years.

Hunter Renfrow is mounting an NFL comeback after spending the 2024 season out of the league battling ulcerative colitis. Here ...

Recent years have seen significant advancements in UC treatment, offering renewed hope for patients seeking effective and ...

Finding a cure for inflammatory bowel disease (IBD) would mean reducing treatment waste, according to Ashwin N.

Research shows that smoking may have beneficial effects on symptoms of ulcerative colitis. But the risks of starting this ...

DelveInsight’s “Ulcerative Colitis Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth ...

Johnson & Johnson (NYSE: JNJ) today announced new data from the TREMFYA® (guselkumab) Phase 3 QUASAR long-term extension (LTE) study in adults with moderately-to-severely active ulcerative colitis (UC ...